Raymond C. Bergan

This paper uses proteomic analysis to show that KBU2046 induces migrastasis in prostate cancer by inhibiting intracellular protein trafficking and altering signaling dynamics.

This paper establishes patient-derived models of neuroendocrine prostate cancer (NEPC) from metastases, showing they retain tumor heterogeneity and can model metastatic progression.

The paper shows that stress increases eHSP90 and KLK6 in prostate cancer cells, which together reduce MMP-2 activity and cell motility.

This paper develops BTE-EN1, a compound that inhibits prostate cancer-mediated bone destruction by targeting cell motility and osteoclast activity, showing efficacy in mice.

The paper uses protein 3D structure analysis to discover novel anticancer compounds by targeting unique structural motifs, identifying Dxr2-017 as a selective inhibitor of melanoma cells.